Diagnostic Approach to Infectious Mononucleosis

Laboratory Evaluation

• The American College of Physicians recommends heterophile antibody test (Monospot) as the most widely used initial test for infectious mononucleosis, which usually becomes positive between the sixth and tenth day after symptom onset 1
• Epstein-Barr virus (EBV) serologic testing is recommended when clinical suspicion remains high despite a negative heterophile test, and should include IgM antibodies to viral capsid antigen (VCA), IgG antibodies to VCA, and antibodies to Epstein-Barr nuclear antigen (EBNA) 1
• The presence of VCA IgM (with or without VCA IgG) antibodies in the absence of EBNA antibodies indicates recent primary EBV infection, while the presence of EBNA antibodies indicates infection more than 6 weeks prior 1

Differential Diagnosis

• Consider other causes of mononucleosis-like illness when rapid Monospot or heterophile tests are negative, including Cytomegalovirus (CMV) infection, HIV infection, Toxoplasma gondii infection, and Adenovirus infection 1

Common Pitfalls and Caveats

• False-positive heterophile antibody results may occur in patients with leukemia, pancreatic carcinoma, viral hepatitis, and CMV infection, while false-negative heterophile results are common early in the course of infection and in young children 1
• Over 90% of normal adults have IgG antibodies to VCA and EBNA antigens, reflecting past infection, and approximately 5-10% of patients who have been infected with EBV fail to develop antibodies to EBNA antigen 1

Infectious Mononucleosis Management and Considerations

Diagnostic Considerations and Special Populations

• The American Gastroenterological Association recommends considering other causes of mononucleosis-like illness, such as HIV infection, in patients with negative heterophile tests 2
• The Centers for Disease Control and Prevention suggests that immunomodulator therapy should be reduced or discontinued if possible in patients with primary EBV infection, and antiviral therapy with ganciclovir or foscarnet may be considered in severe cases 2
• Immunocompromised patients have an increased risk of lymphoproliferative disorders and require careful monitoring, according to the Infectious Diseases Society of America 2

Treatment and Management

• The American Academy of Pediatrics recommends that aciclovir therapy does not ameliorate the course of infectious mononucleosis in otherwise healthy individuals, and corticosteroids should be reserved for specific complications 2

Infectious Mononucleosis Diagnosis

Laboratory Testing Approach

• Lymphocytosis ≥50% of white blood cell differential and atypical lymphocytosis ≥10% of total lymphocyte count support the diagnosis of infectious mononucleosis, according to the Infectious Diseases Society of America 3
• Heterophile antibody test characteristics include a sensitivity of 87% and specificity of 91%, and usually becomes positive between the sixth and tenth day after symptom onset, as reported by the Clinical Infectious Diseases journal 3
• False-negative heterophile results are common in children younger than 10 years and early infection, with an approximate 10% false-negative rate overall, according to the Clinical Infectious Diseases journal 3

Special Populations Requiring Testing

• Immunocompromised patients should be tested more aggressively for infectious mononucleosis due to increased risk of severe disease, lymphoproliferative disorders, and hemophagocytic syndrome, as recommended by the Gut journal 4
• Patients on immunosuppressive therapy, particularly pediatric IBD patients, should be screened for EBV status before initiating thiopurine therapy to prevent primary EBV infection, according to the Gut journal 4

Differential Diagnosis Requiring Alternative Testing

• When heterophile and EBV testing are negative, consider testing for other causes of mononucleosis-like illness, including cytomegalovirus (CMV) infection, HIV infection, Toxoplasma gondii infection, adenovirus infection, and streptococcal pharyngitis, as suggested by the Clinical Infectious Diseases journal 3

Infectious Mononucleosis Treatment in Special Populations

Medication Use and Special Considerations

• The Journal of Crohn's and Colitis recommends that antiviral agents, such as aciclovir, ganciclovir, and foscarnet, have no proven role in established disease in immunocompetent patients 5
• In immunocompromised patients with suspected primary EBV infection, immunomodulator therapy should be reduced or discontinued if possible, according to the Journal of Crohn's and Colitis 5
• The Journal of Crohn's and Colitis suggests that in severe primary EBV infection, antiviral therapy with ganciclovir or foscarnet may be considered despite lack of supporting evidence 5
• Specialist consultation should be sought for suspected lymphoproliferative disease, as recommended by the Journal of Crohn's and Colitis 5
• Primary EBV infection poses a particular threat in patients on thiopurines, with reports of fatal infectious mononucleosis-associated lymphoproliferative disorders, according to the Journal of Crohn's and Colitis 5

Diagnosis and Management of Infectious Mononucleosis (Cited Evidence)

Initial Laboratory Evaluation

• Perform a complete blood count with differential; absolute lymphocytosis with atypical lymphocytes is present in most cases of EBV infectious mononucleosis. 6
• Order a rapid heterophile antibody (Monospot) test as the first‑line serologic screen.

Timing and Interpretation of Heterophile Testing

• The heterophile test typically becomes positive between days 6 and 10 after symptom onset; false‑negative results are common during the first week of illness. 6
• Overall, false‑negative heterophile results occur in approximately 10 % of patients and are especially frequent in children younger than 10 years. 6
• In adolescents, heterophile testing is more reliable than in younger children. 6
• A single negative heterophile result obtained in the first week should not be used to exclude mononucleosis. 6
• When clinical suspicion remains high after an initial negative test, repeat the heterophile assay after 7–10 days or proceed directly to EBV‑specific serology. 6

EBV‑Specific Serologic Panel

• If suspicion persists despite a negative heterophile test, obtain EBV serology immediately, ordering three antibodies together:
• Acute primary infection is indicated by the presence of VCA IgM (with or without VCA IgG) and the absence of EBNA antibodies. 6
• Past infection (> 6 weeks) is confirmed by the presence of EBNA antibodies, effectively ruling out an acute mononucleosis episode. 6
• EBNA antibodies appear 1–2 months after primary infection and persist for life. 6

Differential‑Diagnosis Testing When EBV Results Are Negative or Equivocal

• Consider additional testing for other mononucleosis‑like illnesses, including:

False‑Positive Heterophile Results and Pitfalls

• False‑positive heterophile reactions have been reported in patients with:

Supportive Laboratory Findings

• Liver function tests (AST, ALT, bilirubin) are elevated in roughly 90 % of infectious mononucleosis cases and can reinforce the diagnosis when heterophile testing is negative. 6

Management Recommendations

• Counsel patients to restrict vigorous physical activity for 3–8 weeks to reduce the risk of splenic rupture, a complication occurring in 0.1–0.5 % of cases. 6

Avoidance of Amoxicillin in Suspected EBV Infection

Medication Contraindications

• In patients with suspected Epstein‑Barr virus infection, amoxicillin should be avoided because it precipitates a severe rash in the presence of active EBV infection. 7

Evidence‑Based Management of Primary Epstein‑Barr Virus Infection in Healthy Patients

Diagnostic Confirmation

• Acute primary EBV infection is confirmed by the presence of viral capsid antigen IgM (with or without IgG) and the absence of Epstein‑Barr nuclear antigen antibodies, indicating infection within the past 6 weeks. 8, 9

Antiviral Therapy

• Antiviral agents (aciclovir, ganciclovir, foscarnet) have no proven benefit in altering the clinical course of infectious mononucleosis in immunocompetent individuals; therefore, routine antiviral therapy is not recommended. 8, 9

Corticosteroid Use

• Systemic corticosteroids should be reserved for specific complications such as airway obstruction; they are not indicated for routine treatment of uncomplicated infectious mononucleosis. 8, 9

General Treatment Approach

• Management of typical infectious mononucleosis in otherwise healthy patients is entirely supportive, with no antiviral therapy or routine corticosteroids indicated. 8, 9

Special Population Considerations

• In immunocompromised patients (e.g., those receiving thiopurines or other immunomodulators), the approach differs: immunomodulatory therapy should be reduced or discontinued when feasible, and specialist consultation is advised due to heightened risk of severe disease and lymphoproliferative complications. 8, 9